Pliant Therapeutics
Open
$1.23
Prev. Close
$1.23
High
$1.23
Low
$1.22
Market Snapshot
$74.35M
-0.5
-3.46
49
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
emptyResult
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Recently from Cashu
Pliant Therapeutics: Navigating Market Challenges While Advancing Promising Cancer Therapies
Pliant Therapeutics: Advancing Cancer Therapy Amid Market Challenges Pliant Therapeutics, Inc. is currently at the forefront of the biotech industry with its innovative cancer therapy showing promisin…
Pliant Therapeutics: Advancing Cancer Treatments Amid Stock Volatility and Market Challenges
Pliant Therapeutics: Navigating the Complex Landscape of Cancer Treatment Development Pliant Therapeutics, Inc. is making waves in the biotech sector with recent clinical trial outcomes that showcase…
Pliant Therapeutics: Navigating Market Challenges While Advancing Cancer Therapy Innovations
Pliant Therapeutics: Promising Advances in Cancer Therapy Amid Market Challenges Pliant Therapeutics, Inc. is at the forefront of innovation in the biotech sector, particularly with its latest advance…